Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | ALB | P02768 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | POLG | P54098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16359976 | 1.00 | POLB (0.67) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL3178725 | 1.00 | POLB (0.67) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL25456568 | 1.00 | POLB (0.67) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL2118780 | 0.91 | POLB (0.64) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL3424606 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL3200090 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL1939479 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL5666385 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL15617962 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL1962182 | 0.89 | POLB (0.64) | POLBP2RY2P2RY4P2RY6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | claimed |
| EP-4372091-A2 | COMPOSITIONS AND METHODS FOR EDITING NUCLEIC ACIDS IN CELLS UTILIZING OLIGONUCLEOTIDES | Woolf, Tod M. (US) | 2024-05-22 | — | — | EP | claimed |
| US-20230250474-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-10 | — | — | US | claimed |
| US-11542551-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-01-03 | — | — | US | claimed |
| US-20200318179-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-10-08 | — | — | US | claimed |
| CN-106232834-B | Sample preparation method | 牛津纳米孔技术公司 | 2020-09-22 | — | — | CN | claimed |
| US-10669578-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-06-02 | — | — | US | claimed |
| EP-3108010-B1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECH LTD (GB) | 2018-11-28 | — | — | EP | claimed |
| US-20170067101-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2017-03-09 | — | — | US | claimed |
| EP-3108010-A1 | SAMPLE PREPARATION METHOD | Oxford Nanopore Technologies Limited (GB) | 2016-12-28 | — | — | EP | claimed |
| WO-2015124935-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-08-27 | — | — | WO | claimed |
| WO-2004101822-A2 | USE OF BAGE (B MELANOMA ANTIGENS) LOCI AS TUMOUR MARKERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2004-11-25 | — | — | WO | claimed |
| US-20260117422-A1 | METHODS AND COMPOSITIONS FOR GENOMIC ANALYSIS | Twist Bioscience Corporation (US) | 2026-04-30 | — | — | US | disclosed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260015392-A1 | MUTANT CSGG PORES | OXFORD NANOPORE TECHNOLOGIES PLC (BE) | 2026-01-15 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| WO-1994005684-A1 | N4-METHYL-2'-DEOXYCYTIDINE 5'-TRIPHOSPHATE AND ITS USE IN POLYMERASE-CATALYZED NUCLEIC ACID SYNTHESES | LIFE TECHNOLOGIES, INC. (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0544824-A1 | NUCLEASE RESISTANT, PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION. | ISIS PHARMACEUTICALS INC (US) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992002258-A1 | NUCLEASE RESISTANT, PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECT AND MODULATE GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| EP-0450370-A1 | Branch migration of nucleotides | ENZO BIOCHEM, INC. (US) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | POLB 4/4885P2RY2 181/4885P2RY4 141/4885 |
| US-20260117422-A1 | METHODS AND COMPOSITIONS FOR GENOMIC ANALYSIS | DNMT3A, BRCA1, DNMT1 | POLB 219/4885P2RY2 1082/4885P2RY4 1019/4885 |
| US-20260015392-A1 | MUTANT CSGG PORES | NPPA, AFG3L2, SCAMP3 | POLB 2723/4885P2RY2 1814/4885P2RY4 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.